Toujeo Approval History
- FDA approved: Yes (First approved February 25th, 2015)
- Brand name: Toujeo
- Generic name: insulin glargine [rDNA origin]
- Dosage form: Injection
- Company: Sanofi-Aventis U.S. LLC
- Treatment for: Diabetes, Type 1, Diabetes, Type 2
Toujeo (insulin glargine [rDNA origin] is a once-daily long-acting basal insulin used to improve glycemic control in adults with type 1 and type 2 diabetes.
Development History and FDA Approval Process for Toujeo
|Feb 25, 2015||Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo|
|Jul 8, 2014||FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.